Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.58 |
| ▸ | DRD3 | P35462 | 6/20 | 0.58 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976546 | 0.87 | DRD2 (0.57) | DRD2ADRA1ADRD3HTR1ADRD4 | |
| SCHEMBL8010491 | 0.87 | DRD2 (0.60) | DRD2ADRA1ADRD3HTR1A | |
| SCHEMBL28007048 | 0.84 | HRH3 (0.54) | DRD2ADRA1ADRD3 | |
| SCHEMBL6506385 | 0.84 | CYP1A2 (0.57) | DRD2ADRA1ADRD3KDM4EALDH1A1 | |
| SCHEMBL976063 | 0.83 | ADRA1A (0.73) | DRD2ADRA1ADRD3HTR1AKDM4E | |
| SCHEMBL31690833 | 0.83 | HRH3 (0.56) | DRD2ADRA1ADRD3 | |
| SCHEMBL4616926 | 0.82 | ADRA1A (0.62) | DRD2ADRA1ADRD3HTR1A | |
| SCHEMBL7212266 | 0.81 | HTR1A (0.64) | DRD2ADRA1ADRD3HTR1APIM1 | |
| SCHEMBL27446049 | 0.81 | L3MBTL1 (0.62) | DRD2ADRA1ADRD3KDM4EALDH1A1 | |
| Bromide SCHEMBL7212285 | 0.80 | HTR1A (0.62) | DRD2ADRA1ADRD3HTR1APIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875287-B2 | 99mTc-8-[3-({2-[4-(2-methoxy-phenyl)-piperazine -1-yl]-ethyl}-pyridin-2-yl-amino)-propyl]-[1,2,5,8]dithiadiazecan-6-one; 5-HT1A selective serotonin receptors;receptivity; nonhydrolyzing; radiopharmaceuticals;scanning the brain; neurogenitive deseases; nervous system disorders | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2011-01-25 | — | — | US | disclosed |
| US-20070036715-A1 | 99mTc-8-[3-({2-[4-(2-methoxy-phenyl)-piperazine -1-yl]-ethyl}-pyridin-2-yl-amino)-propyl]-[1,2,5,8]dithiadiazecan-6-one; 5-HT1A selective serotonin receptors;receptivity; nonhydrolyzing; radiopharmaceuticals;scanning the brain; neurogenitive deseases; nervous system disorders | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070036715-A1 | 99mTc-8-[3-({2-[4-(2-methoxy-phenyl)-piperazine -1-yl]-ethyl}-pyridin-2-yl-amino)-propyl]-[1,2,5,8]dithiadiazecan-6-one; 5-HT1A selective serotonin receptors;receptivity; nonhydrolyzing; radiopharmaceuticals;scanning the brain; neurogenitive deseases; nervous system disorders | HTR1A, HTR2A, HTR5A | DRD2 137/4885ADRA1A 35/4885DRD3 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.